Author | Jason M. Broderick

Articles

Updated Cabozantinib Data Includes 6 Patient Deaths

June 08, 2011

Article

Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial, according to data presented at ASCO's annual meeting. The fatalities had not been reported with the cabozantinib data at the May 18 pre-ASCO press briefing. Shares of the drug's manufacturer, Exelixis, fell 20% as investors reacted to the news.

Array BioPharma Has No Shortage of Partners

June 03, 2010

Article

Array BioPharma Inc released its financial results for the third quarter of fiscal 2010, reporting $18.4 million in total revenue for the period but a net loss of $15.2 million, or $0.30 per share.

Overwhelming Cancer Costs Can Cause Post-Traumatic Stress

June 03, 2010

Article

A struggle with cancer is often referred to as a battle. Now, a study reveals patients with cancer and caregivers even experience a condition common to soldiers, post-traumatic stress syndrome.

ASCO Updates Guidelines for Genetic Testing

May 20, 2010

Article

The American Society of Clinical Oncology (ASCO) updated its 2003 recommendations for genetic testing to keep pace with exponential progress in genetic science.

x